{"id":7533,"date":"2025-04-10T09:06:08","date_gmt":"2025-04-10T09:06:08","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7533"},"modified":"2025-04-10T09:06:08","modified_gmt":"2025-04-10T09:06:08","slug":"andres-cervantes-ruiperez","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/andres-cervantes-ruiperez\/","title":{"rendered":"Andr\u00e9s Cervantes Ruip\u00e9rez"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container fusion-parallax-none nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ededed;background-image: url(&quot;https:\/\/www.incliva.es\/wp-content\/uploads\/2021\/01\/fondo.jpg&quot;);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_3_4 3_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-1\" style=\"transform:translate3d(0,0,0);\"><h3>Dr. Andr\u00e9s Cervantes Ruip\u00e9rez<\/h3>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:3px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-2\" style=\"transform:translate3d(0,0,0);\"><h5><span style=\"color: #3D44AC;\">Principal Investigator<br \/>\nResearch Group of Innovative Diagnostic and Therapeutical Developments in Solid Tumors &#8211; InDeST<br \/>\n<\/span><\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-3\" style=\"transform:translate3d(0,0,0);\"><h4 style=\"text-align: justify;\">Presentation<\/h4>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:75% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 2.56%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 2.56%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-0{width:75% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.56%;margin-left : 2.56%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#ffffff;border-width: 0 0 0 2px;border-color:#9da0d2;border-style:solid;padding: 4% 4% 4% 4%;\">\n<div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\" style=\"border-radius:5px;\"><img src=\"\/wp-content\/uploads\/2025\/03\/Andres-Cervantes.jpg\" class=\"img-responsive\"\/><\/span><\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:10px;margin-bottom:10px;width:100%;\"><\/div>\n<div class=\"fusion-text fusion-text-4\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: center;\">Principal<br \/>\nInvestigator<\/h5>\n<div style=\"text-align: center;\">Dr. Andr\u00e9s Cervantes Ruip\u00e9rez<\/div>\n<p style=\"text-align: center;\"><a href=\"mailto:andres.cervantes@uv.es\">andres.cervantes@uv.es<\/a><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 4% !important;padding-right : 4% !important;margin-right : 7.68%;padding-bottom : 4% !important;padding-left : 4% !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-1{width:25% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-fullwidth.fusion-builder-row-1 { overflow:visible; }.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-5\" style=\"transform:translate3d(0,0,0);\"><h5>Publications<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-1 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-1 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-1 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav,.fusion-tabs.fusion-tabs-1 .nav-tabs,.fusion-tabs.fusion-tabs-1 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-a31ddac615a2723b96d\" aria-selected=\"true\" id=\"fusion-tab-2024\" href=\"#tab-a31ddac615a2723b96d\"><h4 class=\"fusion-tab-heading\">2024<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-18cc2b0912093c8d2cb\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2023\" href=\"#tab-18cc2b0912093c8d2cb\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-89958e7705f7aa8e63f\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2022\" href=\"#tab-89958e7705f7aa8e63f\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-576096850eb09ab3efd\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2021\" href=\"#tab-576096850eb09ab3efd\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-a31ddac615a2723b96d\" aria-selected=\"true\" id=\"mobile-fusion-tab-2024\" href=\"#tab-a31ddac615a2723b96d\"><h4 class=\"fusion-tab-heading\">2024<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2024\" id=\"tab-a31ddac615a2723b96d\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nThe role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review. Ciardiello D, Mauri G, Sartore-Bianchi A, Siena S, Zampino M, Fazio N, Cervantes A. Cancer Treatment Reviews. 2024 Jan 12:124:102683. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2024.102683' target='_blank'>10.1016\/j.ctrv.2024.102683<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38237253' target='_blank'>38237253<\/a><\/p>\n<\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-18cc2b0912093c8d2cb\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2023\" href=\"#tab-18cc2b0912093c8d2cb\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2023\" id=\"tab-18cc2b0912093c8d2cb\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nAnti-TIGIT antibody tiragolumab alone or with atezolizumab in patients with advanced solid tumors a Phase 1a\/1b nonrandomized controlled trial. Kim T, Bedard P, Lorusso P, Gordon M, Bendell J, Oh D, Ahn M, Garralda E, D&#8217;Angelo S, Desai J, Hodi F, Wainberg Z, Delord J, Cassier P, Cervantes A, Gil-Martin M, Wu B, Patil N, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho B. JAMA Oncology. 2023 Sep 28:e233867. doi: <a href='https:\/\/doi.org\/10.1001\/jamaoncol.2023.3867' target='_blank'>10.1001\/jamaoncol.2023.3867<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37768658' target='_blank'>37768658<\/a><\/p>\n<p>Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe. Kroese T, van Laarhoven H, Schoppman S, Deseyne P, van Cutsem E, Haustermans K, Nafteux P, Thomas M, Obermannova R, Mortensen H, Nordsmark M, Pfeiffer P, Elme A, Adenis A, Piessen G, Bruns C, Lordick F, Gockel I, Moehler M, Gani C, Liakakos T, Reynolds J, Morganti A, Rosati R, Castoro C, Cellini F, D&#8217;Ugo D, Roviello F, Bencivenga M, de Manzoni G, van Berge Henegouwen M, Hulshof M, van Dieren J, Vollebergh M, van Sandick J, Jeene P, Muijs C, Slingerland M, Voncken F, Hartgrink H, Creemers G, van der Sangen M, Nieuwenhuijzen G, Berbee M, Verheij M, Wijnhoven B, Beerepoot L, Mohammad N, Mook S, Ruurda J, Kolodziejczyk P, Polkowski W, Wyrwicz L, Alsina M, Pera M, Kanonnikoff T, Cervantes A, Nilsson M, Monig S, Wagner A, Guckenberger M, Griffiths E, Smyth E, Hanna G, Markar S, Chaudry M, Hawkins M, Cheong E, van Hillegersberg R, van Rossum P. European Journal of Cancer. 2023 Feb 24;185:28-39. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejca.2023.02.015' target='_blank'>10.1016\/j.ejca.2023.02.015<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36947929' target='_blank'>36947929<\/a><\/p>\n<p>Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Nature Medicine. 2023 Dec 5. doi: <a href='https:\/\/doi.org\/10.1038\/s41591-023-02696-8' target='_blank'>10.1038\/s41591-023-02696-8<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38052910' target='_blank'>38052910<\/a><\/p>\n<p>Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: phase 2 study results. Ciardiello F, Bang Y, Cervantes A, Dvorkin M, Lopez C, Metges J, Ruiz A, Calvo M, Strickland A, Kannourakis G, Muro K, Kawakami H, Wei J, Borg C, Zhu Z, Gupta N, Pelham R, Shen L. Cancer Medicine. 2023 Jun;12(12):13145-13154. doi: <a href='https:\/\/doi.org\/10.1002\/cam4.5997' target='_blank'>10.1002\/cam4.5997<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37260158' target='_blank'>37260158<\/a><\/p>\n<p>Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon D, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y. Lancet Oncology. 2023 Aug;24(8):925-935. doi: <a href='https:\/\/doi.org\/10.1016\/S1470-2045(23)00275-9' target='_blank'>10.1016\/S1470-2045(23)00275-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37541273' target='_blank'>37541273<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7533-1 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7533-1 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7533-1.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7533-1 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7533-1 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7533-1 .panel-title a:hover, #accordion-7533-1 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7533-1 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7533-1 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7533-1\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"3123c6accfc3a4b71\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7533-1\" data-target=\"#3123c6accfc3a4b71\" href=\"#3123c6accfc3a4b71\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2023<\/span><\/a><\/h4><\/div><div id=\"3123c6accfc3a4b71\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nEuropean expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer. Martinelli E, Arnold D, Cervantes A, Stintzing S, Van Cutsem E, Tabernero J, Taieb J, Wasan H, Ciardiello F. Cancer Treatment Reviews. 2023 Apr;115:102541. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2023.102541' target='_blank'>10.1016\/j.ctrv.2023.102541<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36931147' target='_blank'>36931147<\/a><\/p>\n<p>FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer. Cervantes A, Prager GW. ESMO Open. 2023 Feb 20;8(2):100883. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.100883' target='_blank'>10.1016\/j.esmoop.2023.100883<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36812740' target='_blank'>36812740<\/a><\/p>\n<p>How organoids can improve personalized treatment in patients with gastro-esophageal tumors. Cabeza-Segura M, Garcia-Mic\u00f2 B, La Noce M, Nicoletti GF, Conti V, Filippelli A, Fleitas T, Cervantes A, Castillo J, Papaccio F. Current Opinion in Pharmacology. 2023 Feb 23;69:102348. doi: <a href='https:\/\/doi.org\/10.1016\/j.coph.2023.102348' target='_blank'>10.1016\/j.coph.2023.102348<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36842387' target='_blank'>36842387<\/a><\/p>\n<p>In the Literature: january 2023. Martin-Arana J, Gambardella V, Tarazona N, Cejalvo JM, Cervantes A. ESMO Open. 2023 Jan 3;8(1):100763. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100763' target='_blank'>10.1016\/j.esmoop.2022.100763<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36603523' target='_blank'>36603523<\/a><\/p>\n<p>In the literature: July 2023. Gambardella V, Gimeno-Valiente F, Rosell\u00f3 S, Cervantes A. ESMO Open. 2023 Aug;8(4):101612. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101612' target='_blank'>10.1016\/j.esmoop.2023.101612<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37467659' target='_blank'>37467659<\/a><\/p>\n<p>In the Literature: March 2023. Gambardella V, Tarazona N, Roda D, Cervantes A. ESMO Open. 2023 Apr;8(2):101203. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101203' target='_blank'>10.1016\/j.esmoop.2023.101203<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37018871' target='_blank'>37018871<\/a><\/p>\n<p>In the literature: May 2023. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2023 May 15;8(3):101562. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101562' target='_blank'>10.1016\/j.esmoop.2023.101562<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37196398' target='_blank'>37196398<\/a><\/p>\n<p>In the literature: September 2023. Lamarca A, Moreno V, Gambardella V, Cervantes A. ESMO Open. 2023 Oct 16;8(6):102032. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.102032' target='_blank'>10.1016\/j.esmoop.2023.102032<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37852035' target='_blank'>37852035<\/a><\/p>\n<p>Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Journal of Clinical Oncology. 2023 Nov 20;41(33):5080-5089. doi: <a href='https:\/\/doi.org\/10.1200\/JCO.22.02773' target='_blank'>10.1200\/JCO.22.02773<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37967516' target='_blank'>37967516<\/a><\/p>\n<p>Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery &#8211; a five-year follow-up of the RAPIDO Trial. Dijkstra EA, Nilsson PJ, Hospers GAP, Bahadoer RR, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Putter H, Berglund A, Cervantes A, Crolla RMPH, Hendriks MP, Capdevila J, Edhemovic I, Marijnen CAM, van de Velde CJH, Glimelius B, van Etten B. Annals of Surgery. 2023 Oct 1;278(4):e766-e772. doi: <a href='https:\/\/doi.org\/10.1097\/SLA.0000000000005799' target='_blank'>10.1097\/SLA.0000000000005799<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36661037' target='_blank'>36661037<\/a><\/p>\n<p>Long-term platinum-based drug accumulation in cancer-associated fibroblasts promotes colorectal cancer progression and resistance to therapy. Linares J, Sallent-Aragay A, Badia-Ramentol J, Recort-Bascuas A, Mendez A, Manero-Ruperez N, Re DL, Rivas EI, Guiu M, Zwick M, Iglesias M, Martinez-Ciarpaglini C, Tarazona N, Varese M, Hernando-Momblona X, Canellas-Socias A, Orrillo M, Garrido M, Saoudi N, Elez E, Navarro P, Tabernero J, Gomis RR, Batlle E, Pisonero J, Cervantes A, Montagut C, Calon A. Nature Communications. 2023 Feb 10;14(1):746. doi: <a href='https:\/\/doi.org\/10.1038\/s41467-023-36334-1' target='_blank'>10.1038\/s41467-023-36334-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36765091' target='_blank'>36765091<\/a><\/p>\n<p>Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E. Annals of Oncology. 2023 Jan;34(1):10-32. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003' target='_blank'>10.1016\/j.annonc.2022.10.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36307056' target='_blank'>36307056<\/a><\/p>\n<p>Napabucasin plus FOLFIRI in patients with previously treated metastatic colorectal cancer: results from the open-label, randomized phase III CanStem303C Study. Shah M, Yoshino T, Tebbutt N, Grothey A, Tabernero J, Xu R, Cervantes A, Oh S, Yamaguchi K, Fakih M, Falcone A, Wu C, Chiu V, Tomasek J, Bendell J, Fontaine M, Hitron M, Xu B, Taieb J, Van Cutsem E. Clinical Colorectal Cancer. 2022 Nov 11:S1533-0028(22)00125-6. doi: <a href='https:\/\/doi.org\/10.1016\/j.clcc.2022.11.002' target='_blank'>10.1016\/j.clcc.2022.11.002<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36503738' target='_blank'>36503738<\/a><\/p>\n<p>Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A. British Journal of Cancer. 2023 Sep;129(5):797-810. doi: <a href='https:\/\/doi.org\/10.1038\/s41416-023-02349-0' target='_blank'>10.1038\/s41416-023-02349-0<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37474720' target='_blank'>37474720<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R, Mulansari N, Govind Babu K, Lee M, Tan C, Cornelio G, Chong D, Chen L, Tanasanvimon S, Prasongsook N, Yeh K, Chua C, Sacdalan M, Sow Jenson W, Kim S, Chacko R, Syaiful R, Zhang S, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. ESMO Open. 2023 May 24;8(3):101558. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101558' target='_blank'>10.1016\/j.esmoop.2023.101558<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37236086' target='_blank'>37236086<\/a><\/p>\n<p>Pharmacokinetics (PK) of Tiragolumab in first-in-human study in patients with mixed solid tumors (GO30103). Garralda E, Oh D, Italiano A, Bedard P, Delord J, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh C, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho B, Kim T, Wu B. Journal of Clinical Pharmacology. 2023 Dec 17. doi: <a href='https:\/\/doi.org\/10.1002\/jcph.2397' target='_blank'>10.1002\/jcph.2397<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/38105505' target='_blank'>38105505<\/a><\/p>\n<p>Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. Carneiro B, Cavalcante L, Mahalingam D, Saeed A, Safran H, Ma W, Coveler A, Powell S, Bastos B, Davis E, Sahai V, Mikrut W, Longstreth J, Smith S, Weiskittel T, Li H, Borden B, Harvey R, Sahebjam S, Cervantes A, Koukol A, Mazar A, Steeghs N, Kurzrock R, Giles F, Munster P. Clinical Cancer Research. 2023 Nov 20. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1916' target='_blank'>10.1158\/1078-0432.CCR-23-1916<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37982822' target='_blank'>37982822<\/a><\/p>\n<p>Preoperative treatment of locally advanced rectal cancer. Sebag-Montefiore D, Cervantes A, Rodel C. New England Journal of Medicine. 2023 Oct 26;389(17):1631. doi: <a href='https:\/\/doi.org\/10.1056\/NEJMc2309857' target='_blank'>10.1056\/NEJMc2309857<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37888929' target='_blank'>37888929<\/a><\/p>\n<p>Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction. Papaccio F, Garcia-Mico B, Gimeno-Valiente F, Cabeza-Segura M, Gambardella V, Gutierrez-Bravo MF, Alfaro-Cervello C, Martinez-Ciarpaglini C, Rentero-Garrido P, Zuniga-Trejos S, Carbonell-Asins JA, Fleitas T, Rosello S, Huerta M, Sanchez Del Pino MM, Sabater L, Roda D, Tarazona N, Cervantes A, Castillo J. Journal of Experimental &#038; Clinical Cancer Research. 2023 Jan 6;42(1):8. doi: <a href='https:\/\/doi.org\/10.1186\/s13046-022-02591-z' target='_blank'>10.1186\/s13046-022-02591-z<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36604765' target='_blank'>36604765<\/a><\/p>\n<p>Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Spahn J, Li S, Cha E, Riely G, Gettinger S. ESMO Open. 2023 Mar 3;8(2):101160. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101160' target='_blank'>10.1016\/j.esmoop.2023.101160<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36871392' target='_blank'>36871392<\/a><\/p>\n<p>Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer. Gimeno-Valiente F, Mart\u00edn-Arana J, T\u00e9bar-Mart\u00ednez R, Gambardella V, Mart\u00ednez-Ciarpaglini C, Garc\u00eda-Mic\u00f3 B, Mart\u00ednez-Castedo B, Palomar B, Garc\u00eda-Bartolom\u00e9 M, Segu\u00ed V, Huerta M, Moro-Valdezate D, Pla-Mart\u00ed V, P\u00e9rez-Santiago L, Rosell\u00f3 S, Roda D, Cervantes A, Tarazona N. ESMO Open. 2023 Nov 9;8(6):102051. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.102051' target='_blank'>10.1016\/j.esmoop.2023.102051<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37951129' target='_blank'>37951129<\/a><\/p>\n<p>Strategies for improving detection of circulating tumor DNA using next generation sequencing. Roberto T, Jorge M, Francisco G, Noelia T, Pilar R, Andres C. Cancer Treatment Reviews. 2023 Sep;119:102595. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2023.102595' target='_blank'>10.1016\/j.ctrv.2023.102595<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37390697' target='_blank'>37390697<\/a><\/p>\n<p>Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Kroese TE, van Rossum PSN, Nilsson M, Lordick F, Smyth EC, Rosati R, Nafteux P, D&#8217;Ugo D, Chaudry MA, Polkowkski W, Roviello F, Gockel I, Kolodziejczyk P, Haustermans K, Guckenberger M, Nordsmark M, Hawkins MA, Cervantes A, Fleitas T, van Cutsem E, Moehler M, Wagner AD, van Laarhoven HWM, van Hillegersberg R. European Journal of Surgical Oncology. 2023 Jan;49(1):21-28. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejso.2022.09.012' target='_blank'>10.1016\/j.ejso.2022.09.012<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36184420' target='_blank'>36184420<\/a><\/p>\n<p>The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO\/World Congress on Gastrointestinal Cancer, Barcelona, 2022. Ducreux M, Abou-Alfa G, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, Eng C, Galle P, Gill S, Gruenberger T, Haustermans K, Lamarca A, Laurent-Puig P, Llovet J, Lordick F, Macarulla T, Mukherji D, Muro K, Obermannova R, O&#8217;Connor J, O&#8217;Reilly E, Osterlund P, Philip P, Prager G, Ruiz-Garcia E, Sangro B, Seufferlein T, Tabernero J, Verslype C, Wasan H, Van Cutsem E. ESMO Open. 2023 May 30;8(3):101567. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101567' target='_blank'>10.1016\/j.esmoop.2023.101567<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37263081' target='_blank'>37263081<\/a><\/p>\n<p>The percentage of mesorectal infiltration as a prognostic factor after curative surgery for pT3 rectal cancer. Sancho-Muriel J, Giner F, Cholewa H, Garcia-Granero A, Rosell\u00f3 S, Flor-Lorente B, Cervantes A, Garcia-Granero E, Frasson M. Colorectal Disease. 2023 Jun;25(6):1135-1143. doi: <a href='https:\/\/doi.org\/10.1111\/codi.16522' target='_blank'>10.1111\/codi.16522<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36790134' target='_blank'>36790134<\/a><\/p>\n<p>The prognostic potential of CDX2 in colorectal cancer: harmonizing biology and clinical practice. Badia-Ramentol J, Gimeno-Valiente F, Dur\u00e9ndez E, Mart\u00ednez-Ciarpaglini C, Linares J, Iglesias M, Cervantes A, Calon A, Tarazona N. Cancer Treatment Reviews. 2023 Dec:121:102643. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2023.102643' target='_blank'>10.1016\/j.ctrv.2023.102643<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37871463' target='_blank'>37871463<\/a><\/p>\n<p>The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial. Dijkstra E, Zwart W, Nilsson P, Putter H, Roodvoets A, Meershoek-Klein Kranenbarg E, Frodin J, Nygren P, Ostergaard L, Kersten C, Verbiene I, Cervantes A, Hendriks M, Capdevila J, Edhemovic I, van de Velde C, Marijnen C, van Etten B, Hospers G, Glimelius B. ESMO Open. 2023 Mar 3;8(2):101158. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101158' target='_blank'>10.1016\/j.esmoop.2023.101158<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36871393' target='_blank'>36871393<\/a><\/p>\n<p>Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO Metastatic Colorectal Cancer Living Guideline. Cervantes A, Martinelli E. Annals of Oncology. 2023 Nov 7:S0923-7534(23)04335-1. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2023.10.129' target='_blank'>10.1016\/j.annonc.2023.10.129<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37951473' target='_blank'>37951473<\/a><\/p>\n<p>Ximenez E, Ruiperez A. Selective neoadjuvant therapy in locally advanced rectal cancer: Who and why?. Cirugia Espanola. 2023 May;101(5):309-311. doi: <a href='https:\/\/doi.org\/10.1016\/j.cireng.2022.11.007' target='_blank'>10.1016\/j.cireng.2022.11.007<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36423876' target='_blank'>36423876<\/a><\/p>\n<p>Young oncologists&#8217; perspective on the role and future of the clinician-scientist in oncology. Lim K, Westphalen C, Berghoff A, Cardone C, Connolly E, Guven D, Kfoury M, Kocakavuk E, Mando P, Mariamidze E, Matikas A, Moutafi M, Oing C, Pihlak R, Punie K, Sanchez-Bayona R, Sobczuk P, Starzer A, Tecic Vuger A, Zhu H, Cruz-Ordinario M, Altuna S, Canario R, Vuylsteke P, Banerjee S, de Azambuja E, Cervantes A, Lambertini M, Mateo J, Amaral T. Esmo Open. 2023 Aug 31;8(5):101625. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101625' target='_blank'>10.1016\/j.esmoop.2023.101625<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37659290' target='_blank'>37659290<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-89958e7705f7aa8e63f\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2022\" href=\"#tab-89958e7705f7aa8e63f\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2022\" id=\"tab-89958e7705f7aa8e63f\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nCirculating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, towards assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, Sharma S, Renner D, Hafez D, Roda D, Huerta M, Rosello S, Madsen AH, Love US, Andersen PV, Thorlacius-Ussing O, Iversen LH, Gotschalck KA, Sethi H, Aleshin A, Cervantes A, Andersen CL. Clinical Cancer Research. 2022 Feb 1;28(3):507-517. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2404' target='_blank'>10.1158\/1078-0432.CCR-21-2404<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34625408' target='_blank'>34625408<\/a><\/p>\n<p>Clinical management of metastatic colorectal cancer in the era of precision medicine. Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. CA-A Cancer Journal for Clinicians. 2022 Jul;72(4):372-401. doi: <a href='https:\/\/doi.org\/10.3322\/caac.21728' target='_blank'>10.3322\/caac.21728<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35472088' target='_blank'>35472088<\/a><\/p>\n<p>Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. Andreu Y, Martinez P, Soto-Rubio A, Fernandez S, Bosch C, Cervantes A. Supportive Care in Cancer. 2022 Feb;30(2):1483-1491. doi: <a href='https:\/\/doi.org\/10.1007\/s00520-021-06513-1' target='_blank'>10.1007\/s00520-021-06513-1<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34529142' target='_blank'>34529142<\/a><\/p>\n<p>Corrigendum to &#8220;Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up&#8221;: [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2022 Jun;33(6):666. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.03.009' target='_blank'>10.1016\/j.annonc.2022.03.009<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35365377' target='_blank'>35365377<\/a><\/p>\n<p>ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski R, Curigliano G, Felip E, Ferreira A, Ganz P, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge A, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. Annals of Oncology. 2022 Nov;33(11):1119-1133. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1941' target='_blank'>10.1016\/j.annonc.2022.07.1941<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35963481' target='_blank'>35963481<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7533-2 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7533-2 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7533-2.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7533-2 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7533-2 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7533-2 .panel-title a:hover, #accordion-7533-2 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7533-2 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7533-2 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7533-2\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"502b03950598a7574\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7533-2\" data-target=\"#502b03950598a7574\" href=\"#502b03950598a7574\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2022<\/span><\/a><\/h4><\/div><div id=\"502b03950598a7574\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nFirst-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. Italiano A, Cassier PA, Lin C, Alanko T, Peltola KJ, Gazzah A, Shiah HS, Calvo E, Cervantes A, Roda D, Tosi D, Gao B, Millward M, Warburton L, Tanner M, Englert S, Lambert S, Parikh A, Afar DE, Vosganian G, Moreno V. Cancer Immunology Immunotherapy. 2022 Feb;71(2):417-431. doi: <a href='https:\/\/doi.org\/10.1007\/s00262-021-02973-w' target='_blank'>10.1007\/s00262-021-02973-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34216247' target='_blank'>34216247<\/a><\/p>\n<p>First-in-human phase I Study of the OX40 agonist MOXR0916 in patients with advanced solid tumors. Kim T, Burris H, de Miguel Luken M, Pishvaian M, Bang Y, Gordon M, Awada A, Camidge D, Hodi F, McArthur G, Miller W, Cervantes A, Chow L, Lesokhin A, Rutten A, Sznol M, Rishipathak D, Chen S, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu L. Clinical Cancer Research. 2022 Aug 15;28(16):3452-3463. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4020' target='_blank'>10.1158\/1078-0432.CCR-21-4020<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35699599' target='_blank'>35699599<\/a><\/p>\n<p>First-in-human, open-label, phase 1\/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T&#8217;jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Cancer Chemotherapy and Pharmacology. 2022 Apr;89(4):499-514. doi: <a href='https:\/\/doi.org\/10.1007\/s00280-022-04414-6' target='_blank'>10.1007\/s00280-022-04414-6<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35298698' target='_blank'>35298698<\/a><\/p>\n<p>Impact of the COVID-19 pandemic on a cancer fast-track programme. Martinez M, Moragon S, Ortega-Morillo B, Monton-Bueno J, Simon S, Rosello S, Insa A, Viala A, Navarro J, Sanmartin A, Fluixa C, Julve A, Soriano D, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner M, Cano A, Silvestre A, Teruel A, Bermejo B, Cervantes A, Chirivella Gonzalez I. Cancer Control. 2022 Jan-Dec;29:10732748221131000. doi: <a href='https:\/\/doi.org\/10.1177\/10732748221131000' target='_blank'>10.1177\/10732748221131000<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36355430' target='_blank'>36355430<\/a><\/p>\n<p>In the literature: April 2022. Ciardiello D, Roda D, Gambardella V, Cervantes A. ESMO Open. 2022 Apr 23;7(3):100479. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100479' target='_blank'>10.1016\/j.esmoop.2022.100479<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35472677' target='_blank'>35472677<\/a><\/p>\n<p>In the literature: December 2021. Montagut C, Gambardella V, Cabeza-Segura M, Fleitas T, Cervantes A. ESMO Open. 2022 Feb;7(1):100352. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100352' target='_blank'>10.1016\/j.esmoop.2021.100352<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34920292' target='_blank'>34920292<\/a><\/p>\n<p>In the literature: February 2022. Gambardella V, Cejalvo JM, Gonzalez Barrallo I, Gimeno Valiente F, Cervantes A. ESMO open. 2022 Feb 23;7(2):100411. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100411' target='_blank'>10.1016\/j.esmoop.2022.100411<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35219243' target='_blank'>35219243<\/a><\/p>\n<p>In the literature: July 2022. Gambardella V, Martinelli E, Tarazona N, Cervantes A. ESMO Open. 2022 Aug;7(4):100556. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100556' target='_blank'>10.1016\/j.esmoop.2022.100556<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35961192' target='_blank'>35961192<\/a><\/p>\n<p>In the literature: November 2022. Gambardella V, Cejalvo J, Cervantes A. ESMO Open. 2022 Nov 17;7(6):100643. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100643' target='_blank'>10.1016\/j.esmoop.2022.100643<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36403559' target='_blank'>36403559<\/a><\/p>\n<p>Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcon-Molero L, Gonzalez-Vilanova A, Zuniga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Dura A, Richart P, Alonso N, Huerta M, Rosello S, Roda D, Tarazona N, Martinez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. British Journal of Cancer. 2022 Dec;127(12):2198-2206. doi: <a href='https:\/\/doi.org\/10.1038\/s41416-022-02005-z' target='_blank'>10.1038\/s41416-022-02005-z<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36253523' target='_blank'>36253523<\/a><\/p>\n<p>Minimal residual disease in gastroesophageal adenocarcinoma: thesearch for the invisible. Tarazona N, Gimeno-Valiente F, Cervantes A. ESMO Open. 2022 Aug;7(4):100547. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2022.100547' target='_blank'>10.1016\/j.esmoop.2022.100547<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35849878' target='_blank'>35849878<\/a><\/p>\n<p>Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003' target='_blank'>10.1016\/j.annonc.2022.07.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35914638' target='_blank'>35914638<\/a><\/p>\n<p>Paclitaxel induces epidermal molecular changes and produces subclinical alterations in the skin of gynecological cancer patients. Montero P, Perez-Leal M, Perez-Fidalgo JA, Sanz C, Estornut C, Roger I, Milara J, Cervantes A, Cortijo J. Cancers. 2022 Feb 23;14(5):1146. doi: <a href='https:\/\/doi.org\/10.3390\/cancers14051146' target='_blank'>10.3390\/cancers14051146<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35267454' target='_blank'>35267454<\/a><\/p>\n<p>Quality of life in cancer survivorship: Sociodemographic and disease-related moderators. Andreu Y, Martinez P, Soto-Rubio A, Perez-Marin M, Cervantes A, Arribas L. European Journal of Cancer Care. 2022 Nov;31(6):e13692. doi: <a href='https:\/\/doi.org\/10.1111\/ecc.13692' target='_blank'>10.1111\/ecc.13692<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36069249' target='_blank'>36069249<\/a><\/p>\n<p>RUNAT-BI: A Ruthenium(III) Complex as a Selective Anti-Tumor Drug Candidate against Highly Aggressive Cancer Cell Lines. Albanell-Fernandez M, Oltra S, Orts-Arroyo M, Ibarrola-Villava M, Carrasco F, Jimenez-Marti E, Cervantes A, Castro I, Martinez-Lillo J, Ribas G. Cancers. 2022 Dec 22;15(1):69. doi: <a href='https:\/\/doi.org\/10.3390\/cancers15010069' target='_blank'>10.3390\/cancers15010069<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36612065' target='_blank'>36612065<\/a><\/p>\n<p>SMG8\/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance. Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, Dylewska M, Broderick R, Brough R, Zimmermann A, Zenke FT, Gurel B, Riisnaes R, Ferreira A, Roumeliotis T, Choudhary J, Pettitt SJ, de Bono J, Cervantes A, Haider S, Niedzwiedz W, Lord CJ, Chong IY. Cancer Research. 2022 Nov 2;82(21):3962-3973. doi: <a href='https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-4339' target='_blank'>10.1158\/0008-5472.CAN-21-4339<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36273494' target='_blank'>36273494<\/a><\/p>\n<p>SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, Gonzalez B, Arance A, Martin-Liberal J, Gavila J, Lopez-Gonzalez A, Miguel Cejalvo J, Izarzugaza Y, Amillano K, Garcia Corbacho J, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesia R, Cervantes A, Tabernero J. Future Oncology. 2022 Oct 6. doi: <a href='https:\/\/doi.org\/10.2217\/fon-2022-0660' target='_blank'>10.2217\/fon-2022-0660<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36200668' target='_blank'>36200668<\/a><\/p>\n<p>The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally. Van Schooten T, Derks S, Jimenez-Marti E, Carneiro F, Figueiredo C, Ruiz E, Alsina M, Molero C, Garrido M, Riquelme A, Caballero C, Lezcano E, O&#8217;Connor J, Esteso F, Farres J, Mas J, Lordick F, Vogt J, Cardone A, Girvalaki C, Cervantes A, Fleitas T. BMC Cancer. 2022 Jun 13;22(1):646. doi: <a href='https:\/\/doi.org\/10.1186\/s12885-022-09689-9' target='_blank'>10.1186\/s12885-022-09689-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35692051' target='_blank'>35692051<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-576096850eb09ab3efd\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2021\" href=\"#tab-576096850eb09ab3efd\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2021\" id=\"tab-576096850eb09ab3efd\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nBeyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia J, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S. ESMO Open. 2021 Jul 24;6(5):100237. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100237' target='_blank'>10.1016\/j.esmoop.2021.100237<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411971' target='_blank'>34411971<\/a><\/p>\n<p>Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant\u00a0therapy. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 May;32(5):590-599. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.02.004' target='_blank'>10.1016\/j.annonc.2021.02.004<\/a>. Epub 2021 Feb 17. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33609722' target='_blank'>33609722<\/a><\/p>\n<p>Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Huerta M, Rosello S, Sabater L, Ferrer A, Tarazona N, Roda D, Gambardella V, Alfaro-Cervello C, Garces-Albir M, Cervantes A, Ibarrola-Villava M. Cancers. 2021 Feb 27;13(5):994. doi: <a href='https:\/\/doi.org\/10.3390\/cancers13050994' target='_blank'>10.3390\/cancers13050994<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33673558' target='_blank'>33673558<\/a><\/p>\n<p>Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. Pavlidis N, Peccatori F, Aapro M, Cervantes Ruiperez A, Stahel R, Eniu A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Oct;36(5):1124-1128. doi: <a href='https:\/\/doi.org\/10.1007\/s13187-020-01744-y' target='_blank'>10.1007\/s13187-020-01744-y<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32303982' target='_blank'>32303982<\/a><\/p>\n<p>Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Gambardella V, Martinez-Ciarpaglini C, Fleitas T, Cervantes A. ESMO Open. 2021 Nov 6;6(6):100285. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100285' target='_blank'>10.1016\/j.esmoop.2021.100285<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34752996' target='_blank'>34752996<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7533-3 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7533-3 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7533-3.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7533-3 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7533-3 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7533-3 .panel-title a:hover, #accordion-7533-3 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7533-3 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7533-3 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7533-3\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"2add6906da6901ee7\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7533-3\" data-target=\"#2add6906da6901ee7\" href=\"#2add6906da6901ee7\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2021<\/span><\/a><\/h4><\/div><div id=\"2add6906da6901ee7\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nEpigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer. Gimeno-Valiente F, Riffo-Campos A, Torres L, Tarazona N, Gambardella V, Cervantes A, Lopez-Rodas G, Franco L, Castillo J. Cancers. 2021 Mar 21;13(6):1433. doi: <a href='https:\/\/doi.org\/10.3390\/cancers13061433' target='_blank'>10.3390\/cancers13061433<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33801071' target='_blank'>33801071<\/a><\/p>\n<p>ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. Annals of Oncology. 2021 Jul;32(7):823-824. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.04.001' target='_blank'>10.1016\/j.annonc.2021.04.001<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34090547' target='_blank'>34090547<\/a><\/p>\n<p>ESMO pays tribute to Professor Jose Baselga. Peters S, Tabernero J, Cervantes A, Banerjee S, Giuliani R, Lordick F. ESMO open. 2021 Jul;32(7):823-824. doi: 10.1016\/j.annonc.2021.04.001. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34144776' target='_blank'>34144776<\/a><\/p>\n<p>ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. Pavlidis N, Peccatori F, Aapro M, Eniu A, Stahel R, Cervantes A, Cavalli F, Costa A. Journal of Cancer Education. 2021 Jun;36(3):556-560. doi: <a href='https:\/\/doi.org\/10.1007\/s13187-019-01664-6' target='_blank'>10.1007\/s13187-019-01664-6<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/31845109' target='_blank'>31845109<\/a><\/p>\n<p>First-in-human phase I study of a next-generation, oral, transforming growth factor-beta receptor 1 inhibitor, LY3200882 in patients with advanced cancer. Yap TA, Vieito M, Baldini C, Sepulveda-Sanchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Lohr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. Clinical Cancer Research. 2021 Dec 15;27(24):6666-6676. doi: <a href='https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1504' target='_blank'>10.1158\/1078-0432.CCR-21-1504<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34548321' target='_blank'>34548321<\/a><\/p>\n<p>First-line biological agents plus chemotherapy in older patients with metastatic colorectal cancer: a retrospective pooled analysis. Garcia-Alfonso P, Diaz-Rubio E, Abad A, Carrato A, Massuti B, Ortiz-Morales M, Mozo J, Munoz A, Duran G, Sastre J, Safont M, Ferreiro R, Rivera F, Gonzalez E, Valladares-Ayerbes M, Gravalos C, Alonso-Orduna V, Vieitez J, Yubero A, Aranda E, Spanish Cooperative Grp Treatment. Drugs &#038; Aging. 2021 Mar;38(3):219-231. doi: <a href='https:\/\/doi.org\/10.1007\/s40266-021-00834-w' target='_blank'>10.1007\/s40266-021-00834-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33615402' target='_blank'>33615402<\/a><\/p>\n<p>Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, Gandini S, Lizier M, Braga D, Asnicar F, Segata N, Klaver C, Brescia P, Rossi E, Anselmo A, Guglietta S, Maroli A, Spaggiari P, Tarazona N, Cervantes A, Marsoni S, Lazzari L, Jodice M, Giovanna L, Chiara E, Marco PS, Di Fiore PP, Viale G, Spinelli A, Pozzi C, Penna G, Rescigno M. Cancer Cell. 2021 May 10;39(5):708-724.e11. doi: <a href='https:\/\/doi.org\/10.1016\/j.ccell.2021.03.004' target='_blank'>10.1016\/j.ccell.2021.03.004<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33798472' target='_blank'>33798472<\/a><\/p>\n<p>In the literature: April 2021. Martin-Martorell P, Gonzalez-Barrallo I, Gambardella V, Cejalvo J M, Cervantes A. ESMO open. 2021 Apr 19;6(3):100116. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100116' target='_blank'>10.1016\/j.esmoop.2021.100116<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33887688' target='_blank'>33887688<\/a><\/p>\n<p>In the literature: August 2021. Gambardella V, Alfaro-Cervello C, Cejalvo J, Tapia M, Cervantes A. ESMO Open. 2021 Aug 16;6(5):100247. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100247' target='_blank'>10.1016\/j.esmoop.2021.100247<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411970' target='_blank'>34411970<\/a><\/p>\n<p>In the literature: December 2020. Gambardella V, Ibarrola-Villaba M, Tarazona N, Cervantes A. ESMO Open. 2021 Jan 4;6(1):100009. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2020.100009' target='_blank'>10.1016\/j.esmoop.2020.100009<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33399075' target='_blank'>33399075<\/a><\/p>\n<p>In the literature: February 2021. Cejalvo J, Gambardella V, Fleitas T, Cervantes A. ESMO Open. 2021 Feb 24;6(2):100061. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100061' target='_blank'>10.1016\/j.esmoop.2021.100061<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33639602' target='_blank'>33639602<\/a><\/p>\n<p>In the literature: June 2021. Gambardella V, Candia L, Tapia M, Cejalvo JM, Cervantes A. ESMO open. 2021 Jun;6(3):100186. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100186' target='_blank'>10.1016\/j.esmoop.2021.100186<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34098228' target='_blank'>34098228<\/a><\/p>\n<p>Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. Gambardella V, Lombardi P, Carbonell-Asins JA, Tarazona N, Cejalvo JM, Gonzalez-Barrallo I, Martin-Arana J, Tebar-Martinez R, Viala A, Bruixola G, Hernando C, Blasco I, Papaccio F, Martinez-Ciarpaglini C, Alfaro-Cervello C, Seda-Garcia E, Blesa S, Chirivella I, Castillo J, Monton-Bueno JV, Rosello S, Huerta M, Perez-Fidalgo A, Martin-Martorell P, Insa-Molla A, Fleitas T, Rentero-Garrido P, Zuniga-Trejos S, Cervantes A, Roda D. British Journal of Cancer. 2021 Oct;125(9):1261-1269. doi: <a href='https:\/\/doi.org\/10.1038\/s41416-021-01502-x' target='_blank'>10.1038\/s41416-021-01502-x<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34493820' target='_blank'>34493820<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1752' target='_blank'>10.1016\/j.annonc.2021.08.1752<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411693' target='_blank'>34411693<\/a><\/p>\n<p>Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. Pellino G, Garcia-Granero E, Cervantes A. European Journal of Surgical Oncology. 2021 Oct;47(10):2697. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejso.2021.06.031' target='_blank'>10.1016\/j.ejso.2021.06.031<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34217579' target='_blank'>34217579<\/a><\/p>\n<p>Radiomics and radiogenomics in head and neck squamous cell carcinoma: potential contribution to patient management and challenges. Bruixola G, Remacha E, Jimenez-Pastor A, Dualde D, Viala A, Monton J, Ibarrola-Villava M, Alberich-Bayarri A, Cervantes A. Cancer Treatment Reviews. 2021 Sep;99:102263. doi: <a href='https:\/\/doi.org\/10.1016\/j.ctrv.2021.102263' target='_blank'>10.1016\/j.ctrv.2021.102263<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34343892' target='_blank'>34343892<\/a><\/p>\n<p>Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. Smyth EC, Gambardella V, Cervantes A, Fleitas T. Annals of Oncology. 2021 Sep;32(9):1190-1191. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.05.795' target='_blank'>10.1016\/j.annonc.2021.05.795<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34033882' target='_blank'>34033882<\/a><\/p>\n<p>Retrospective study of regorafenib versus TAS-102 efficacy and safety in chemorefractory Metastatic Colorectal Cancer (mCRC) patients: a multi-institution real life clinical data. Vitale P, Zanaletti N, Famiglietti V, De Falco V, Cervantes A, Rosell\u00f2 S, Fenocchio E, Milanesio M, Lombardi P, Ciardiello D, Martini G, Martinelli E, Ciardiello F, Troiani T, Napolitano S. Clinical Colorectal Cancer. 2021 Sep;20(3):227-235. doi: <a href='https:\/\/doi.org\/10.1016\/j.clcc.2021.06.002' target='_blank'>10.1016\/j.clcc.2021.06.002<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34226142' target='_blank'>34226142<\/a><\/p>\n<p>Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Bahadoer R, Dijkstra E, van Etten B, Marijnen C, Putter H, Kranenbarg E, Roodvoets A, Nagtegaal I, Beets-Tan R, Blomqvist L, Fokstuen T, Ten Tije A, Capdevila J, Hendriks M, Edhemovic I, Cervantes A, Nilsson P, Glimelius B, van de Velde C, Hospers G, RAPIDO collaborative investigators. Lancet. Oncology. 2021 Jan;22(1):29-42. doi: <a href='https:\/\/doi.org\/10.1016\/S1470-2045(20)30555-6' target='_blank'>10.1016\/S1470-2045(20)30555-6<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33301740' target='_blank'>33301740<\/a><\/p>\n<p>Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib. Malhi V, Budha N, Sane R, Huang J, Liederer B, Meng R, Patel P, Deng Y, Cervantes A, Tabernero J, Musib L. Cancer Chemotherapy and Pharmacology. 2021 Dec;88(6):921-930. doi: <a href='https:\/\/doi.org\/10.1007\/s00280-021-04344-9' target='_blank'>10.1007\/s00280-021-04344-9<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34471960' target='_blank'>34471960<\/a><\/p>\n<p>Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. Martinez MT, Monton-Bueno J,  Simon S, Ortega B, Moragon S, Rosello S, Insa A, Navarro J, Sanmartin A, Julve A, Buch E, Pena A, Franco J, Martinez-Jabaloyas J, Marco J, Forner MJ, Cano A, Silvestre A, Teruel A, Lluch A, Cervantes A, Chirivella Gonzalez I. ESMO open. 2021 May 11;6(3):100148. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100148' target='_blank'>10.1016\/j.esmoop.2021.100148<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33989988' target='_blank'>33989988<\/a><\/p>\n<p>The COVID-19 pandemic could be a setback for gender equality in oncology-and a key moment to push ahead with transformative policies. Cervantes A. ESMO Open. 2021 Jun;6(3):100169. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2021.100169' target='_blank'>10.1016\/j.esmoop.2021.100169<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34144777' target='_blank'>34144777<\/a><\/p>\n<p>Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective  analysis and critical assessment of a 10-year prospective national registry on  behalf of the Spanish Rectal Cancer Project. Pellino G, Al\u00f3s R, Biondo S, Codina-Cazador A, Enr\u00edquez-Navascues J, Esp\u00edn-Basany E, Roig-Vila J, Cervantes Ruiperez A, Carceller R, Spanish Rectal Cancer Project collaborators. EJSO. 2021 Feb;47(2):276-284. doi: <a href='https:\/\/doi.org\/10.1016\/j.ejso.2020.04.056' target='_blank'>10.1016\/j.ejso.2020.04.056<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32950316' target='_blank'>32950316<\/a><\/p>\n<p>Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014' target='_blank'>10.1016\/j.annonc.2021.02.014<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33716105' target='_blank'>33716105<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-2{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-2 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-2{width:100% !important;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-2{width:100% !important;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #9da0d2;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-6\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: left;\">Projects<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-2 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-2 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-2 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav,.fusion-tabs.fusion-tabs-2 .nav-tabs,.fusion-tabs.fusion-tabs-2 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-3aca1be18da2af1d84e\" aria-selected=\"true\" id=\"fusion-tab-projects\" href=\"#tab-3aca1be18da2af1d84e\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-3aca1be18da2af1d84e\" aria-selected=\"true\" id=\"mobile-fusion-tab-projects\" href=\"#tab-3aca1be18da2af1d84e\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-projects\" id=\"tab-3aca1be18da2af1d84e\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:left;\">\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>101057514 &#8211; Mypath<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Developing and implementing innovative Patient-Centred Care Pathways for cancer patients<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2027<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>388,125 (Total: 4,773,470.00)\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI21\/00689<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Caracterizaci\u00f3n y abordaje de la enfermedad m\u00ednima residual en c\u00e1ncer de colon localizado: un paso hacia la medicina de precisi\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Noelia Tarazona Llavero, Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>232.320 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>ICI20\/00009<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Investigaci\u00f3n Cl\u00ednica Independiente<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>1.039.970 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PT20\/00100<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Plataforma de Investigaci\u00f3n Cl\u00ednica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>199.650 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>825832 \u2013 LEGACy<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>CeLac and European consortium for a personalized medicine approach to Gastric Cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>\u20ac3.577.431,27 (INCLIVA: \u20ac638.315)\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI18\/01909<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Medicina personalizada en pacientes con c\u00e1ncer colorrectal localizado: abordaje multi\u00f3mico de la Enfermedad M\u00ednima Residual en biopsia l\u00edquida y modelos de organoides<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez, Desamparados Roda<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>141.570 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PT17\/0017\/0003<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Plataforma de Investigaci\u00f3n y Ensayos Cl\u00ednicos<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2018 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>266.475 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>CB16\/12\/00473<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>CIBER Oncolog\u00eda (CIBERONC)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2017 &#8211;<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>AC15\/00096<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Evolution of resistant clones to novel target-directed drugs in colorectal tumours. A genetic and apigenetic study of intratumoral herterogeneity dynamics<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission (Programaci\u00f3n conjunta internacional ISCIII)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Andr\u00e9s Cervantes Ruip\u00e9rez<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2016 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>29.645 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>MoTriColor<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Josep Tabernero<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2015 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>271.424 \u20ac\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-3{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-3 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-3{width:100% !important;order : 0;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-3{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-7\" style=\"transform:translate3d(0,0,0);\"><h5>+ Info<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-3 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-3 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-3 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav,.fusion-tabs.fusion-tabs-3 .nav-tabs,.fusion-tabs.fusion-tabs-3 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-a8ff52dc5ed4a322f1e\" aria-selected=\"true\" id=\"fusion-tab-clinicalguides\" href=\"#tab-a8ff52dc5ed4a322f1e\"><h4 class=\"fusion-tab-heading\">CLINICAL GUIDES<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-397b8f3c5b944da875e\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-thesis\" href=\"#tab-397b8f3c5b944da875e\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-a8ff52dc5ed4a322f1e\" aria-selected=\"true\" id=\"mobile-fusion-tab-clinicalguides\" href=\"#tab-a8ff52dc5ed4a322f1e\"><h4 class=\"fusion-tab-heading\">CLINICAL GUIDES<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-clinicalguides\" id=\"tab-a8ff52dc5ed4a322f1e\">Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer. Yoshino T, Cervantes A, Bando H, Martinelli E, Oki E, Xu R, Mulansari N, Govind Babu K, Lee M, Tan C, Cornelio G, Chong D, Chen L, Tanasanvimon S, Prasongsook N, Yeh K, Chua C, Sacdalan M, Sow Jenson W, Kim S, Chacko R, Syaiful R, Zhang S, Curigliano G, Mishima S, Nakamura Y, Ebi H, Sunakawa Y, Takahashi M, Baba E, Peters S, Ishioka C, Pentheroudakis G. ESMO Open. 2023 May 24;8(3):101558. doi: <a href='https:\/\/doi.org\/10.1016\/j.esmoop.2023.101558' target='_blank'>10.1016\/j.esmoop.2023.101558<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37236086' target='_blank'>37236086<\/a><\/p>\n<p>Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J, Seligmann J, De Baere T, Osterlund P, Yoshino T, Martinelli E. Annals of Oncology. 2023 Jan;34(1):10-32. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.10.003' target='_blank'>10.1016\/j.annonc.2022.10.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36307056' target='_blank'>36307056<\/a><\/p>\n<p>Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Obermannova R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken N, Vogel A, Smyth E. Annals of Oncology. 2022 Oct;33(10):992-1004. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2022.07.003' target='_blank'>10.1016\/j.annonc.2022.07.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35914638' target='_blank'>35914638<\/a><\/p>\n<p>Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. Vogel A, Martinelli E, ESMO Guidelines Commite. Annals of Oncology. 2021 Jun;32(6):801-805. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.02.014' target='_blank'>10.1016\/j.annonc.2021.02.014<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33716105' target='_blank'>33716105<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D, Mishima S, Li Y, Smruti B, Ahn J, Faud I, Chee C, Yeh K, Lin P, Chua C, Hasbullah H, Lee M, Sharma A, Sun Y, Curigliano G, Bando H, Lordick F, Yamanaka T, Tabernero J, Baba E, Cervantes A, Ohtsu A, Peters S, Ishioka C, Pentheroudakis G. Annals of Oncology. 2021 Dec;32(12):1496-1510. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1752' target='_blank'>10.1016\/j.annonc.2021.08.1752<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34411693' target='_blank'>34411693<\/a><\/p>\n<p>New Guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing. Tarazona Llavero N, Roda Perez D, Rosell\u00f3 Ker\u00e4nen S, Huerta Alvaro M, Cervantes Ruiperez A. Annals of Oncology. 2020 Oct;31(10):1287-1288. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2020.07.012' target='_blank'>10.1016\/j.annonc.2020.07.012<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32710931' target='_blank'>32710931<\/a><\/p>\n<p>Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Chen L, Martinelli E, Cheng A, Pentheroudakis G, Qin S, Bhattacharyya G, Ikeda M, Lim H, Ho G, Choo S, Ren Z, Malhotra H, Ueno M, Ryoo B, Kiang T, Tai D, Vogel A, Cervantes Ruiperez A, Lu S, Yen C, Huang Y, Chen S, Hsu C, Shen Y, Tabernero J, Yen Y, Hsu C, Yoshino T, Douillard J. Annals of Oncology. 2020 Mar;31(3):334-351. doi: <a href='https:\/\/doi.org\/10.1016\/j.annonc.2019.12.001' target='_blank'>10.1016\/j.annonc.2019.12.001<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/32067677' target='_blank'>32067677<\/a><\/p>\n<p>Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balma\u00f1a J, Martinelli E; ESMO Guidelines Committee. Annals of Oncology. 2019 Oct 1;30(10):1558-1571. doi: <a href='https:\/\/doi.org\/10.1093\/annonc\/mdz233' target='_blank'>10.1093\/annonc\/mdz233<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/31378807' target='_blank'>31378807<\/a><\/p>\n<p>Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 29, pg iv238, 2018). Vogel A,\u00a0Cervantes A,\u00a0Chau I,\u00a0Daniele B,\u00a0Llovet JM,\u00a0Meyer T,\u00a0Nault JC,\u00a0Neumann U,\u00a0Ricke J,\u00a0Sangro B,\u00a0Schirmacher P,\u00a0Verslype C,\u00a0Zech CJ,\u00a0Arnold D,\u00a0Martinelli E. Annals of Oncology. 2019 May 1;30(5):871-873. doi: <a href='https:\/\/doi.org\/10.1093\/annonc\/mdy510' target='_blank'>10.1093\/annonc\/mdy510<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/30715202' target='_blank'>30715202<\/a><\/p>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-397b8f3c5b944da875e\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-thesis\" href=\"#tab-397b8f3c5b944da875e\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-thesis\" id=\"tab-397b8f3c5b944da875e\"><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Tecnolog\u00edas de secuenciaci\u00f3n masiva y PCR digital en la detecci\u00f3n de ADN tumoral procedente de tejido y plasma en pacientes de colon localizado<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>T\u00e9bar Mart\u00ednez, Roberto<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Rentero Garrido, Pilar; Cervantes Ruip\u00e9rez, Andr\u00e9s; Tarazona Llavero, Noelia<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>01\/02\/2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Establecimiento de organoides derivados de pacientes con carcinoma colorrectal como modelo para cribado de drogas con acci\u00f3n antitumoral<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Guti\u00e9rrez Bravo, M\u00aa Fernanda<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Castillo Aliaga, Josefa; Cervantes Ruip\u00e9rez, Andr\u00e9s<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>04\/02\/2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Multi-omic characterization of advanced colorectal cancer patients derived organoids in the context of Precision Medicine<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Papaccio, Federica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Cervantes Ruip\u00e9rez, Andr\u00e9s; Castillo Aliaga, Josefa<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>23\/12\/2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universit\u00e0 della Campania Luigi Vanvitelli<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>A multi-omic liquid biopsy-based signature as a valuable tool to assess minimal residual disease in localised colorectal cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Tarazona Llavero, Noelia<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Cervantes Ruip\u00e9rez, Andr\u00e9s<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>23\/07\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Genetic determinants of atr inhibitor sensitivity and resistance in gastric cancer<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Llorca Carde\u00f1osa, Marta Jessica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Cervantes Ruip\u00e9rez, Andr\u00e9s; Ribas Despuig, Gloria<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>22\/07\/2019<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-4{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-4 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-4{width:100% !important;order : 0;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-4{width:100% !important;order : 0;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-4{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7533"}],"collection":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/comments?post=7533"}],"version-history":[{"count":0,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7533\/revisions"}],"wp:attachment":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/media?parent=7533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}